FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology and immunology. Variable domains of heavy (VH) and light (VL) chains of mouse monoclonal antibodies against human alpha-defensins 1–3 (HNP 1–3), as well as an antigen-binding fragment of Fab, which selectively bind to alpha-defensins 1-3 (HNP 1–3) of a human being.
EFFECT: present invention can find further application in diagnosing intraarticular infection of large joints.
3 cl, 9 tbl, 5 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
| VARIABLE DOMAINS OF LIGHT AND HEAVY CHAIN OF THE MOUSE MONOCLONAL ANTIBODY AGAINST INTERFERON ALPHA (IFN-α) HUMAN ANTIGEN BINDING FRAGMENTS (FAb) AGAINST HUMAN IFN-α COMPRISING SAID DOMAINS | 2018 |
|
RU2694672C1 |
| ANAPHYLATOXIN C5A ANTIBODIES TO HUMAN | 2019 |
|
RU2731516C1 |
| RECOMBINANT Fab-scFv BASED ON A NEUTRALISING ANTIBODY AGAINST HUMAN BETA-1A INTERFERON AND AN ANTIBODY AGAINST HUMAN ErbB2 RECEPTOR | 2019 |
|
RU2748953C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| HUMANISED ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (FAB) AGAINST FIRST AND/OR SECOND TYPE SHIGA LIKE TOXINS (EMBODIMENTS), COMPOSITION FOR TREATING ENTEROHAEMORRHAGIC ESCHERICHIA COLI TOXIC CONDITIONS, CONTAINING SAID ANTIBODIES AND/OR FAB | 2019 |
|
RU2732155C1 |
